Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses

Platelets

Volumn 16, Issue 7, 2005, Pages 398-407

  Judge, Heather M ^a   Buckland, Robert J ^a   Holgate, Carol E ^a   Storey, Robert F ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Glycoprotein IIb IIIa; P2Y12; PCI; Platelet activation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AR C 69931MX; CANGRELOR; CD40 LIGAND; CLOPIDOGREL; COLLAGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; LIPOCORTIN 5; PROCOAGULANT; PROTEIN INHIBITOR; PURINE P2Y12 RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOXANE A2; TIROFIBAN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; BLOOD CLOTTING; BLOOD SAMPLING; CELL SECRETION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; NORMAL HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN SECRETION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE MONOPHOSPHATE; ANTIBODIES, MONOCLONAL; ASPIRIN; BLOOD PLATELETS; CD40 LIGAND; COAGULANTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MEMBRANE PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, PURINERGIC P2; RECEPTORS, THROMBIN; SECRETORY VESICLES; TYROSINE;

EID: 27644562205     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100500163226     Document Type: Article

References (27)

1. 3. Thrombosis and Haemostasis 1997;78:220-225.
2. Massberg S, Mueller I, Besta F, Thomas P, Gawaz M. Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting. American Heart Journal 2003;146:E19.
3. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003;107:1123-1128.
4. 12, a new platelet ADP receptor, target of clopidogrel. Biochemical and Biophysical Research Communications 2001;283:379-383.
5. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2003;13:407-413.
6. 2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. British Journal of Haematology 2000;110:925-934.
7. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thrombosis and Haemostasis 2001;85:401-407.
8. Storey RF, Wilcox RD, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant and antagonist potency. Circulation 1998;98:1616-1621.
9. Matzdorff AC, Kuhnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J. Effect of glycoprotein IIb/IIIa inhibitors on CD62P expression, platelet aggregates and microparticles in vitro. Journal of Laboratory and Clinical Medicine 2000;135:247-255.
10. Dachery-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometry study showing a role for free sulfhydryl groups. Blood 1993;81(10):2554-2565.
11. Trumel C, Payraste B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave J, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999;94(12):4156-4165.
12. 2, and adenosine diphosphate in collagen-induced platelet aggregation. Blood 2003;101:2646-2651.
13. Gawaz M, Ruf A, Pogatsa-Murray G, Dickfield T, Rudiger S, Taubitz W, Fischer J, Muller I, Meier D, Patscheke H, Schomig A. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: Importance of internal pool of glycoprotein IIb-IIIa receptors. Thrombosis and Haemostasis 2000;83:915-922.
14. Tsao PW, Forsythe MS, Mousa SA. Dissociation between the anti-aggregatory and anti-secretory effects of platelet integrin αIIbβ3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thrombosis Research 1997;88(2):137-146.
15. Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. Journal of the American College of Cardiology 2004;43(11):1982-1988.
16. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. Journal of the American College of Cardiology 2004;43(12):2319-2325.
17. Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thrombosis and Haemostasis 2003;90:377-384.
18. Schönbeck U, Libby P. CD40 signalling and plaque stability. Circulation Research 2001;89:1092-1103.
19. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forgang K, Froland SS, Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Circulation 1999;100:614-620.
20. André P, Srinivasa KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a b3 integrin-dependent mechanism. Nature Medicine 2002;8(3):247-252.
21. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular disease. Cardiovascular Research 2003;59:277-287.
22. Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 2000;95:1317-1323.
23. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. Journal of Clinical Investigation 1998;102:136-144.
24. Biró É, Sturk-Maquelin KN, Vogel GMT, Meuleman DG, Smit MJ, Hack CE, Sturk, Nieuwland R. Human cell-derived microparticles promote thrombus formation in vivo in a tissue-factor-dependent manner. Journal of Thrombosis and Haemostasis 2003;1:2561-2568.
25. Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thrombosis and Haemostasis 2002;88:488-494.
26. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: The platelet paradigm. Blood 1998;91(8):2645-2657.
27. Cazes E, Nurden P, Nurden AT. Abciximab binding to glycoprotein IIb-IIIa and protein tyrosine phosphorylation in human platelets. Blood 1999;93(11):4019-4027.